Advancing the Science of Analgesic Assessment in Chronic Musculoskeletal Disease (Eli Lilly and Company Supported Lunch Symposia)

This 1-hour symposium reviews how osteoarthritis analgesic trial methods have evolved, using COX-2 inhibitors, anti-NGF therapies, and incretin analogues to illustrate how study design elements—duration, populations, imaging, endpoints— account for intervention biology and patient goals. It highlights how different mechanisms create distinct evidentiary challenges, requiring tailored assumptions on onset, durability, and symptom–structure relationships. The session also addresses interpreting analgesic benefit alongside safety tradeoffs and the role and limits of imaging, emphasizing that long-term outcomes such as joint replacement will ultimately be the most definitive indicator of disease modification.